These results validated the findings of the GeneSpring analysis of clinical data, which indicated markedly increased RhoA levels in ccRCC of TNM stages 1–2 compared with the levels in ccRCC of stages 3 and 4 versus their paired normal tissues. The gene discussed is RHOA; the disease is nonpapillary renal cell carcinoma.